New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
NCT ID NCT07637851
First seen Jun 12, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants will receive three cycles of the combination, then maintenance therapy for up to 15 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Eugène Marquis
Rennes, 35042, France
Contact
-
Centre François Baclesse
Caen, 14076, France
Contact
-
Centre Georges François Leclerc
Dijon, 21079, France
Contact
-
Centre Léon Bérard
Lyon, 69373, France
Contact
-
Gustave Roussy
Villejuif, 94805, France
Contact
-
HCL - Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
Contact
-
Hôpital de Hautepierre
Strasbourg, 67098, France
Contact
-
ICM Val d'Aurelle
Montpellier, 34298, France
Contact
-
ICO - Centre René Gauducheau
Saint-Herblain, 44805, France
Contact
-
Institut Bergonié
Bordeaux, 33076, France
Contact
-
Institut Paoli Calmettes
Marseille, 13273, France
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.